Cigna : No turn-around in sight
Entry price | Target | Stop-loss | Potential |
---|
$238.4 |
$265 |
$224 |
+11.16% |
---|
Cigna Corporation shares show a positive technical situation which suggests a continuation of the upward dynamic over the medium term.
Summary● Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
● The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths● The company's attractive earnings multiples are brought to light by a P/E ratio at 14.98 for the current year.
● The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
● Given the positive cash flows generated by its business, the company's valuation level is an asset.
Weaknesses● According to forecast, a sluggish sales growth is expected for the next fiscal years.
● The company's earnings growth outlook lacks momentum and is a weakness.
● As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
● Over the past twelve months, analysts' consensus has been significantly revised downwards.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.